论文部分内容阅读
为进一步研究体外细胞实验筛选出的多药耐药逆转剂在体内的药效学，将其中Ｆｗ １３ 的ｔｅ４１ 用于人白血病Ｋ５６２／ＡＤＲ裸鼠移植瘤逆转试验。结果显示：对ＢＡＬＢ／ｃ－ｎｕ／ｎｕ 荷瘤鼠按每日、每只腹腔注射ＦＷ１３－ｔｅ４１０．２ｍ ｌ（相当于原生药０．２ｇ），连续注射１８ 日后，可将硫酸长春新碱（ＶＣＲ）对Ｋ５６２ ／ＡＤＲ的抑瘤率从１９．７９％ 提高到８６．５９％ ，与ＶＣＲ组比较有显著性差异（Ｐ＜ ０．０５）。提示该中药制剂对恶性肿瘤多药耐药具有较强的逆转作用，可望成为安全有效的化疗致敏剂。
In order to further study the in vitro pharmacodynamics of multidrug resistance reversal agents screened in vitro, the te41 of Fw 13 was used in the reversal test of human leukemia K562/ADR xenograft in nude mice. The results showed that the BALB/c-nu/nu tumor-bearing mice were injected with FW13-te410.2 ml per day (equivalent to 0.2 g of protoic drug) intraperitoneally and intraperitoneally. After continuous injection for 18 days, vincristine sulfate was used ( The inhibition rate of VCR on K562/ADR increased from 19.79% to 86.59%, which was significantly different from that of VCR group (P<0.05). It is suggested that the traditional Chinese medicine preparation has a strong reversal effect on multidrug resistance of malignant tumors and is expected to become a safe and effective chemotherapy sensitizer.